Kardigan, Inc.

NASDAQ:KARD

Biotechnology

Healthcare
$12.32 +3.50%

+$0.77 today

Market cap
$1.10B
Beta
0.00
52W Low $16.25High $24.00

Volume 0.55M

Average 5.84M

KARD Net Income

Bottom-line profit, the starting point for calculating cash from operations.

No reported Net Income figures are available to summarize.

Net Income history

Currency unavailable · from the cash flow

No Net Income data reported for this period type.

Net Income vs competitors

How KARD compares with its peers on the latest reported figures

KARD Competitors
Net Income for KARD and competitors
Company Period LTM YoY 3-year CAGR% of revenue
CYTKCytokinetics, IncorporatedLTM Jun 2026$894M USD+47.4%+26.4%1259.9%
NAMSNewAmsterdam Pharma Company N.V.LTM Jun 2026$147.97M USD-10.7%+108.0%2078.0%
TNYATenaya Therapeutics, Inc.LTM Mar 2026$83.01M USD-21.5%-9.9%36891.1%
IKTInhibikase Therapeutics, Inc.LTM Mar 2026$50.96M USD+39.4%+38.8%—
RNAAtrium Therapeutics, Inc.FY2025$49.5M USD——265.9%
KARDKardigan, Inc.—— ———
Peer median (excluding KARD) —+14.4%+32.6%1668.9%

Competitors are the stored peer set for KARD. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Kardigan, Inc.

NASDAQ:KARD

Intrinsic Alpha fair value

Locked

Current Price

$12.32

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.